Roche's Competitive Advantage

Apr 11 2014, 8:18am CDT | by

Roche Holdings has managed to grow its revenues and earnings at an impressive rate, whereas other big pharmaceutical firms have suffered due to several major drugs losing patent protection. Roche has distinguished itself due to its focus on biotechnology research and development (R&D) and leadership in oncology (cancer therapeutics). Given that the R&D productivity has declined over the years as far as small molecules are concerned, and the fact that there is a visible shift towards targeted therapies, Roche stands to gain. In this analysis we’ll look at Roche’s competitive advantage and how it fits in the shifting pharmaceutical landscape.

Our price estimate for Roche stands at $36.80, which is roughly inline with the market price.

See our complete analysis for Roche

Dominance In The Growing Cancer Market
/>

Roche has one of the strongest and most profitable drug portfolios in cancer therapeutics market. Three of its major drugs Rituxan/MabThera, Avastin and Herceptin are used for treating a variety of cancer forms including blood cancer, breast cancer and colorectal cancer. The combined sales from these drugs stood at over CHF 19.28 billion in 2013, or roughly $21.8 billion at the current exchange rate. This accounted for around 53% of Roche’s total pharmaceutical revenues during the year. Additionally, its total oncology (cancer therapeutics) sales constituted roughly 62% of its pharmaceuticals business which clearly showcases Roche’s success in this area. Despite the fact that individual sales of Rituxan/MabThera, Avastin and Herceptin stood between $6.8 and $7.8 billion, their growth was still healthy. Avastin saw its revenues jump by 13% in 2013 due to its demand for the treatment of ovarian cancer in Europe and increased use for colorectal cancer in both, Europe and the U.S.

The opportunity in oncology comes from the fact that global incidence of cancer is expected to increase from about 12.7 million in 2008 to 21.3 million in 2030. In addition, the number of deaths is likely to show a similar growth trajectory as depicted in the chart below. Treating Cancer can be tricky as it is a not a single disease, and has more than 200 types and thousands of subtypes affecting more than 60 organs. This means that the medicines have to be very specific and targeted. Being the biggest biotech firm in the world with a strong technical know-how, Roche has developed several biologics to treat cancer. Unlike small molecule drugs, biologics tend to be more targeted and attach themselves to specific cell receptors associated with the disease process.

Biologics Are The Way To Go As Small Molecule Drug R&D Productivity Declines
/>

Roche has maintained strong focus on biotech research and development (R&D), especially since its acquisition of Genentech. In both absolute terms and as a percentage of revenues, it spends more amount on R&D activities as compared to its competitors such as Pfizer, Merck and Johnson & Johnson. The company currently has 14 biopharmaceutical drugs in the market and another 39 investigational biopharmaceuticals in its drug pipeline. Additionally, seven of its 10 highest selling drugs are biopharmaceuticals. Given that R&D productivity has declined for small molecule drugs over the last few years, biologics may be the way to go. The shift is clear as 71% of the revenue generated by top 10 drugs in 2012 came from biotech products.

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)
/>

Like our charts? Embed them in your own posts using the Trefis WordPress Plugin.

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

Finnish scientists identify new type of black hole
Helsinki, Oct 31 (IANS) Finnish researchers have discovered a new type of low-mass black hole, which is a bright celestial body that emits X-ray, the University of Turku has said.
 
 
Union Carbide ex-chief Warren Anderson is dead
Washington, Oct 31 (IANS) Warren Anderson, former chief executive officer of the Union Carbide Corporation, is dead, a media report said Friday. He was 92.
 
 
Himalayan Viagra fuels gold rush for local Tibetans
Washington, Oct 31 (IANS) Overwhelmed by people trying to find the prized medicinal fungus known as Himalayan Viagra, two isolated Tibetan communities have managed to implement a successful system for the sustainable harvest of the precious natural resource, suggests research.
 
 
Oceans were always there on Earth: Scientists
Washington, Oct 31 (IANS) Debunking previous theories that water came late to Earth well after the planet had formed, researchers have significantly moved back the clock for the first evidence of water on Earth and in the inner solar system.
 
 
 

Latest from the Network

Koji Uerhara Signs 2-Year, $18M Deal With Boston Red Sox
Ace Japanese closer Koji Uehara signed a two-year deal with the Boston Red Sox on Oct. 30.According to MLB.com's Ian Browne, Uehara's deal is worth $18 million:"Perhaps it was fitting that the Red Sox announced a two-...
Read more on Sport Balla
 
Finnish scientists identify new type of black hole
Helsinki, Oct 31 (IANS) Finnish researchers have discovered a new type of low-mass black hole, which is a bright celestial body that emits X-ray, the University of Turku has said. Researchers at the Finnish university...
Read more on Business Balla
 
Union Carbide ex-chief Warren Anderson is dead
Washington, Oct 31 (IANS) Warren Anderson, former chief executive officer of the Union Carbide Corporation, is dead, a media report said Friday. He was 92. His death revived memories of the 1984 Bhopal gas tragedy. He...
Read more on Business Balla
 
Himalayan Viagra fuels gold rush for local Tibetans
Washington, Oct 31 (IANS) Overwhelmed by people trying to find the prized medicinal fungus known as Himalayan Viagra, two isolated Tibetan communities have managed to implement a successful system for the sustainable...
Read more on Business Balla
 
Oceans were always there on Earth: Scientists
Washington, Oct 31 (IANS) Debunking previous theories that water came late to Earth well after the planet had formed, researchers have significantly moved back the clock for the first evidence of water on Earth and in...
Read more on Business Balla
 
Wearable health devices key for safe space tourism
New York, Oct 31 (IANS) At a time when several firms are developing spacecrafts to take ordinary citizens on short trips into space, scientists have outlined the risks and challenges involved in human commercial...
Read more on Business Balla
 
Early Walmart Cyber Monday 2014 Sale and Holiday 2014 Sale announced
Walmart has revealed their first Holiday 2014 sales details. Starting Saturday Walmart will offer over 20,000 rollback deals. New this year are early Walmart Cyber Monday 2014 sales starting midnight on walmart.com.On...
Read more on Black Friday Countdown
 
Nestle to introduce robots as sales clerks
Tokyo, Oct 31 (IANS/EFE) Nestle will use robots as sales clerks at its outlets selling coffee makers in Japan, an initiative that will later spread worldwide, a Nestle spokesperson confirmed to EFE news agency....
Read more on Celebrity Balla
 
Healthy diet for infants prevents obesity later
New York, Oct 31 (IANS) If you do not want your baby to grow up into an overweight adult, make sure you feed him or her healthy diet from the very first year, a study suggests. Babies who eat diets high in sugar, fat...
Read more on Business Balla
 
Popular mosquito catcher in Japan uses human odour as bait
Tokyo, Oct 31 (IANS) A novel mosquito trap that lures its prey using human scent and other smells favoured by the critter is creating a buzz as Japan frets about the spread of dengue fever. The boxlike device is the...
Read more on Business Balla